Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that ...

China granted Priority Review for an at-home Alzheimer’s treatment developed by Biogen and Eisai. ・If approved, the ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of ...

Biogen is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer’s therapies, driving improved mix quality. Learn more about BIIB stock here.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Analysts expect earnings of $1.61 per share on revenue of $2.21 billion for the quarter ended December. Those figures represent a sharp sequential decline from the third quarter, when Biogen posted $2 ...

The Food and Drug Administration on Monday approved Biogen's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living ...

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...